LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedI
Invus
Activity from announced rounds
Activity in this selectionsimplyhealth-ventures-98030ada
- Rounds participated in
- 6
- Confirmed lead rounds
- — 6 roles undisclosed
- New companies
- 6 First participation on record · 0 follow-on
- Funding in participating rounds
- $1B 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in this selectionCity Therapeutics
Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas
$99.5MSeries B
Role not disclosedContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosedFlexiv
Develops and manufactures adaptive robots for complex tasks
UndisclosedStrategic
Role not disclosedMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed